Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

511 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study.
Visco C, Rodeghiero F, Romano A, Valeri F, Merli M, Quaresimini G, Volpetti S, Santi RM, Carli G, Lucchini E, Passamonti F, Rambaldi A, Motta G, Borchiellini A, d'Amore ESG, Ruggeri M. Visco C, et al. Among authors: carli g. Blood. 2019 Nov 14;134(20):1708-1711. doi: 10.1182/blood.2019001617. Blood. 2019. PMID: 31570488 Free article. Clinical Trial.
Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival.
Visco C, Falisi E, Young KH, Pascarella M, Perbellini O, Carli G, Novella E, Rossi D, Giaretta I, Cavallini C, Scupoli MT, De Rossi A, D'Amore ES, Rassu M, Gaidano G, Pizzolo G, Ambrosetti A, Rodeghiero F. Visco C, et al. Among authors: carli g. Oncotarget. 2015 Jul 30;6(21):18653-63. doi: 10.18632/oncotarget.4418. Oncotarget. 2015. PMID: 26087198 Free PMC article.
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.
De Stefano V, Carobbio A, Di Lazzaro V, Guglielmelli P, Iurlo A, Finazzi MC, Rumi E, Cervantes F, Elli EM, Randi ML, Griesshammer M, Palandri F, Bonifacio M, Hernandez-Boluda JC, Cacciola R, Miroslava P, Carli G, Beggiato E, Ellis MH, Musolino C, Gaidano G, Rapezzi D, Tieghi A, Lunghi F, Loscocco GG, Cattaneo D, Cortelezzi A, Betti S, Rossi E, Finazzi G, Censori B, Cazzola M, Bellini M, Arellano-Rodrigo E, Bertozzi I, Sadjadian P, Vianelli N, Scaffidi L, Gomez M, Cacciola E, Vannucchi AM, Barbui T. De Stefano V, et al. Among authors: carli g. Blood Cancer J. 2018 Feb 28;8(3):25. doi: 10.1038/s41408-018-0048-9. Blood Cancer J. 2018. PMID: 29535299 Free PMC article. Clinical Trial.
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
Olivieri J, Mosna F, Pelosini M, Fama A, Rattotti S, Giannoccaro M, Carli G, Tisi MC, Ferrero S, Sgherza N, Mazzone AM, Marino D, Calimeri T, Loseto G, Saraceni F, Tomei G, Sica S, Perali G, Codeluppi K, Billio A, Olivieri A, Orciuolo E, Matera R, Stefani PM, Borghero C, Ghione P, Cascavilla N, Lanza F, Chiusolo P, Finotto S, Federici I, Gherlinzoni F, Centurioni R, Fanin R, Zaja F; Fondazione Italiana Linfomi Postgraduate Master Course. Olivieri J, et al. Among authors: carli g. Biol Blood Marrow Transplant. 2018 Sep;24(9):1814-1822. doi: 10.1016/j.bbmt.2018.05.018. Epub 2018 May 29. Biol Blood Marrow Transplant. 2018. PMID: 29857196 Free article.
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting.
De Stefano V, Rocca B, Tosetto A, Soldati D, Petrucci G, Beggiato E, Bertozzi I, Betti S, Carli G, Carpenedo M, Cattaneo D, Cavalca V, Dragani A, Elli E, Finazzi G, Iurlo A, Lanzarone G, Lissandrini L, Palandri F, Paoli C, Rambaldi A, Ranalli P, Randi ML, Ricco A, Rossi E, Ruggeri M, Specchia G, Timillero A, Turnu L, Vianelli N, Vannucchi AM, Rodeghiero F, Patrono C. De Stefano V, et al. Among authors: carli g. Blood Cancer J. 2018 Jun 1;8(6):49. doi: 10.1038/s41408-018-0078-3. Blood Cancer J. 2018. PMID: 29880847 Free PMC article. Clinical Trial.
Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma.
Tisi MC, Paolini R, Piazza F, Ravelli E, Tecchio C, Sartori R, Famengo B, D'Amore ESG, Carli G, Perbellini O, Di Bona E, Ruggeri M, Visco C. Tisi MC, et al. Among authors: carli g. Am J Hematol. 2018 Dec;93(12):E386-E389. doi: 10.1002/ajh.25278. Epub 2018 Oct 9. Am J Hematol. 2018. PMID: 30184246 Free article. Clinical Trial. No abstract available.
511 results